Evaluation of a multidrug chemotherapy protocol with mitoxantrone based maintenance (CHOP-MA) for the treatment of canine lymphoma

The purpose of this study was to evaluate the efficacy of adding mitoxantrone to a cyclophosphamide, doxorubicin, vincristine, l-asparaginase and prednisone containing protocol. Sixty-five dogs with multicentric lymphoma were evaluated for overall remission and survival times. Remission and survival...

Full description

Saved in:

Bibliographic Details
Published in:	Veterinary & comparative oncology Vol. 8; no. 1; pp. 11 - 22
Main Authors:	Daters, A.T, Mauldin, G.E, Mauldin, G.N, Brodsky, E.M, Post, G.S
Format:	Journal Article
Language:	English
Published:	Oxford, UK Oxford, UK : Blackwell Publishing Ltd 01-03-2010 Blackwell Publishing Ltd
Subjects:	adverse effects Animals Antineoplastic Combined Chemotherapy Protocols - therapeutic use asparaginase Asparaginase - administration & dosage Asparaginase - therapeutic use canine chemotherapy combination drug therapy cyclophosphamide Cyclophosphamide - administration & dosage Cyclophosphamide - therapeutic use dog diseases Dog Diseases - drug therapy Dogs dosage doxorubicin Doxorubicin - administration & dosage Doxorubicin - therapeutic use drug toxicity Female lymphoma Lymphoma - drug therapy Lymphoma - veterinary Male mitoxantrone Mitoxantrone - administration & dosage Mitoxantrone - therapeutic use mortality multicentric lymphoma prednisone Prednisone - administration & dosage Prednisone - therapeutic use remission steroids vincristine Vincristine - administration & dosage Vincristine - therapeutic use
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	The purpose of this study was to evaluate the efficacy of adding mitoxantrone to a cyclophosphamide, doxorubicin, vincristine, l-asparaginase and prednisone containing protocol. Sixty-five dogs with multicentric lymphoma were evaluated for overall remission and survival times. Remission and survival time versus stage, substage, pretreatment hypercalcaemia and pretreatment steroid administration were also evaluated. Overall median remission for dogs with multicentric lymphoma was 302 days and overall median survival was 622 days. Of the dogs with multicentric lymphoma, 23 (35%) received all scheduled mitoxantrone doses. Only median survival versus substage was found to be significant (substage a median survival was 679 days and substage b median survival was 302 days, P = 0.025). Increasing the total combined dose of doxorubicin and mitoxantrone may improve remission times when compared with historical controls, and further studies are needed to determine how best to utilize mitoxantrone in multidrug chemotherapy protocols for canine multicentric lymphoma.
Bibliography:	http://dx.doi.org/10.1111/j.1476-5829.2009.00199.x ark:/67375/WNG-38LN7XW7-1 istex:89DE73E0B12660655BFB1E62F4D6A984352FE1FB ArticleID:VCO199 Present address: Cancer Centre for Animals, Western Veterinary Specialist and Emergency Centre, 1802‐10th Avenue SW, Calgary, Alberta, Canada T3C 0J8. Present address: Veterinary Oncology and Hematology Center, 178 Connecticut Avenue, Norwalk, CT 06854, USA. ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23
ISSN:	1476-5810 1476-5829
DOI:	10.1111/j.1476-5829.2009.00199.x